Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioLineRx (BLRX) Net Margin: 2023-2025

Historic Net Margin for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to -666.78%.

  • BioLineRx's Net Margin fell 59839.00% to -666.78% in Q2 2025 from the same period last year, while for Jun 2025 it was -44.67%, marking a year-over-year increase of 27294.00%. This contributed to the annual value of -39.01% for FY2024, which is 95110.00% up from last year.
  • Latest data reveals that BioLineRx reported Net Margin of -666.78% as of Q2 2025, which was up 13.74% from -772.94% recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Net Margin ranged from a high of 2,092.06% in Q4 2023 and a low of -1,376.34% during Q3 2023.
  • In the last 3 years, BioLineRx's Net Margin had a median value of -358.85% in 2024 and averaged -242.18%.
  • The largest annual percentage gain for BioLineRx's Net Margin in the last 5 years was 130,024bps (2024), contrasted with its biggest fall of 209,160bps (2024).
  • BioLineRx's Net Margin (Quarterly) stood at 2,092.06% in 2023, then slumped by 209,160bps to 0.46% in 2024, then tumbled by 59,839bps to -666.78% in 2025.
  • Its Net Margin was -666.78% in Q2 2025, compared to -772.94% in Q1 2025 and 0.46% in Q4 2024.